The many abilities of omalizumab and the unbeaten path

We appreciated the article by Cardet and Casale,1 who focused on the current status of omalizumab treatment in its authorized applications (ie, severe allergic asthma not controlled by standard therapy and chronic spontaneous urticaria not controlled by antihistamines), as well as off-label use in a number of other IgE-mediated or non –IgE-mediated diseases.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Correspondence Source Type: research